BCL2 and diabetic kidney disease: In conclusion, our work shows that the dual inhibition therapy with LCZ696 had protective benefits against HFD/STZ-induced diabetic nephropathy by reducing oxidative stress and inflammation by regulating NF-κB and Bax/Bcl-2/caspase-3 signaling pathways.